UMN Startup Could Shake Up Medical Device Market
A new University of Minnesota startup company is aiming to commercialize two revolutionary cardiovascular-related products.
Vascudyne, launched by the University of Minnesota Technology Commercialization department, plans to develop bioengineered tissue using research by Dr. Robert Tranquillo.
“We are excited about the prospects of this material [becoming] a clinical reality with its commercialization by Vascudyne,” said Dr. Tranquillo, Stem Cell Institute.
The products offered by Vascudyne have regenerative capabilities which are unmatched in the market today.
“Professor Tranquillo’s innovative cardiovascular tissue platform is well positioned to help the field take this important step into the future,” said Luke Brewster in an interview with Twin Cities Business.
You may also like:
Perlingeiro’s lab, over several years, pioneered the development of muscle stem/progenitor cells from pluripotent stem cells in vitro.
Researchers create the first 3D in vitro model capable of isolating specific metastatic cells.
Currently, team members are pursuing projects that will have wide-ranging impacts throughout the state.